Facilities

SQUARE Pharmaceuticals Ltd. (SPL) has three GMP compliant production sites. SPL product range covers: tablet, capsule, liquid orals, inhaler, injectable, suppository, topical preparations like powder, cream, ointment etc. All the plants at Dhaka site are built as per the GMP requirements of US-FDA. UNICEF, Copenhagen has approved Solid Dosage plant of Dhaka Site in 2002 for its Global Supply. The Facility is UK-MHRA approved since 2007 and TGA from 2012. Cephalosporin plant at Dhaka site is a standalone, state-of-the-art manufacturing facility and is TGA certified from 2012. Square is the first to introduce 'Modular Aseptic Compact' system to produce recombinant human insulin in Bangladesh. Objective is to manufacture world class insulin preparations at an affordable price.

Formulation Unit Dhaka

The Dhaka Unit is about 50 km away in the north of the capital city. Bovis Lend Lease, UK designed this plant. This is a state of the art manufacturing facility for oral solid dosage forms and all facilities have been developed meeting the requirements of cGMP CFR 21. Dhaka Unit started its operation at the end of 2002.

In the year 2002, the representative of UNICEF, Copenhagen, audited Dhaka Unit facility and enlisted this plant for their global supply. Besides UNICEF audit, in 2003, David Begg Associates, an UK based consulting company also audited this facility and recognized that this plant fulfills the requirement of MHRA (United Kingdom Medicines and Healthcare Products Regulatory Agency).